Adderall XR Cost in Pennsylvania 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Is Adderall XR and Why Does Pennsylvania Pricing Matter?

Adderall XR is an extended-release oral capsule containing mixed amphetamine salts (75% dextroamphetamine, 25% levoamphetamine) approved by the FDA for attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 and older [1]. Pennsylvania is home to roughly 13 million residents, and CDC data show that approximately 9.4% of U.S. children aged 2 to 17 have received an ADHD diagnosis, a rate that translates to over 500,000 affected Pennsylvania children alone [2]. Adults carry a similar burden; an estimated 4.4% of U.S. adults meet ADHD criteria, and many are treated with stimulant medications long-term [3].

Pricing in Pennsylvania follows national pharmacy benefit rules but is shaped by the state's Medicaid program (Medical Assistance), private insurer formularies, and the availability of 503A compounding pharmacies operating under Pennsylvania law. The ongoing national Adderall shortage, formally recognized by the FDA in October 2022 and still affecting supply chains into 2026, pushes some patients toward compounded or alternative formulations [4].

The landmark MTA Cooperative Group study (N=579, Arch Gen Psychiatry 1999) established that medication management with stimulants produced significantly better ADHD outcomes than behavioral therapy alone, making continued access to these medications a genuine clinical priority rather than a lifestyle preference [5].

Adderall XR List Price vs. Actual Cash Price in Pennsylvania

The Teva brand Adderall XR carries a wholesale acquisition cost near $260 per month for a typical 30-capsule supply, but almost no cash-paying patient in Pennsylvania actually pays that figure. Generic mixed amphetamine salts extended-release capsules from manufacturers including Teva, Amneal, and Lannett bring the retail price down significantly [6].

With a free GoodRx or RxSaver coupon, Pennsylvania pharmacies including CVS, Rite Aid, and Giant Pharmacy typically dispense 30 capsules of generic Adderall XR 20 mg for approximately $25 to $35 per month as of mid-2026. Independent pharmacies in Philadelphia and Pittsburgh may price slightly higher or lower depending on their contracted dispensing fees. The average across Pennsylvania retail chains is approximately $30 per month for the generic [7].

Patients who pay full list price without any discount card are leaving substantial money on the table. A 2020 JAMA study found that discount card pricing was lower than insurance copays for one in four common drugs examined, including stimulants [8]. Carrying both a GoodRx card and your insurance card to the pharmacy counter, then asking the pharmacist to run both, takes less than two minutes and regularly saves $40 to $80 per fill.

Pennsylvania Medicaid Coverage for Adderall XR

Pennsylvania Medical Assistance (Medicaid) covers mixed amphetamine salts extended-release for both ADHD and narcolepsy, which are the two FDA-approved indications listed in the product label [1]. Coverage is available with prior authorization (PA) for most managed care plans operating under Pennsylvania's HealthChoices program.

The prior authorization process typically requires documentation of an ADHD diagnosis consistent with DSM-5 criteria, confirmation that the prescriber is a licensed provider in Pennsylvania, and in some cases a brief medical necessity attestation [9]. Pediatric patients generally face a shorter PA pathway than adults. Pennsylvania's Department of Human Services publishes a preferred drug list (PDL) that places generic mixed amphetamine salts on Tier 2, meaning lower cost-sharing and a relatively straightforward PA requirement compared to brand-only agents [10].

For Medicaid enrollees who receive coverage, the copay is typically $1 to $3 per prescription at a participating pharmacy. Pennsylvania expanded Medicaid under the Affordable Care Act, so adults earning up to 138% of the federal poverty level may qualify [11]. Enrollees can check eligibility through COMPASS, Pennsylvania's benefits portal.

"Stimulant medications remain first-line pharmacotherapy for ADHD across the lifespan," states the American Academy of Pediatrics 2019 Clinical Practice Guideline for ADHD, which also notes that access barriers including cost are associated with treatment discontinuation and worse outcomes [9].

Private Insurance and Employer Plans in Pennsylvania

Most commercial insurance plans available through Pennsylvania's health exchange and through major employers cover generic mixed amphetamine salts at Tier 1 or Tier 2, which means a copay of $10 to $45 per month for most enrollees. Brand-name Adderall XR from Teva typically sits at Tier 3 or higher, where coinsurance can reach 30 to 50% of the list price [12].

Large Pennsylvania employers, including those in the Philadelphia suburban corridor and Pittsburgh's health-system sector, commonly contract with pharmacy benefit managers (PBMs) such as Express Scripts, CVS Caremark, and OptumRx. Each PBM maintains its own formulary, so two patients with the same insurer but different PBM contracts may pay different amounts. Checking the formulary tier before filling a prescription prevents surprise bills.

Key steps for Pennsylvania patients on commercial insurance:

1. Log into your insurer's member portal and search for "amphetamine salts ER" or the NDC number for your specific generic.
2. Note the tier and the copay or coinsurance rate.
3. Ask whether a step therapy waiver applies if your prescriber has already tried other stimulants without success.
4. If the brand is required and cost-prohibitive, ask your prescriber to submit a medical necessity appeal citing the FDA-approved indication and the clinical trial evidence from the MTA study [5].

A 2022 Health Affairs analysis found that prior authorization requirements for ADHD medications delayed treatment initiation by a median of 11 days among commercially insured adults, a finding with direct implications for Pennsylvania patients navigating insurer PA processes [13].

Manufacturer and Pharmacy Savings Programs in Pennsylvania

Teva, the original manufacturer of Adderall XR, has historically offered a savings card for commercially insured patients that reduces the brand copay to as low as $30 per month, though eligibility excludes Medicaid, Medicare, and other government-funded plans [6]. The card is typically redeemable at major Pennsylvania retail chains and must be activated on Teva's patient savings website before the first fill.

Generic manufacturers including Amneal and Lannett do not offer individual savings cards, but their products are already priced low enough that discount cards from GoodRx, RxSaver, and Blink Health bring the cost to the $25 to $35 range described above [7].

The National Alliance on Mental Illness (NAMI) Pennsylvania chapter maintains a resource list of patient assistance programs (PAPs) for residents who do not qualify for Medicaid but cannot afford medication costs. Teva's PAP can supply brand Adderall XR at no cost for qualifying low-income patients who apply with documentation of income and a signed prescriber form [14].

A 2021 JAMA Internal Medicine study found that patient assistance programs reached only about 1% of eligible patients, largely due to complex enrollment requirements [15]. Pennsylvania patients who want to pursue a PAP should ask their prescriber's office to assign a staff member to complete the enrollment paperwork, since most programs require a physician signature and practice letterhead.

Compounded Mixed Amphetamine Salts in Pennsylvania: Legality and Cost

Compounded mixed amphetamine salts are legal in Pennsylvania when prepared by a licensed 503A pharmacy operating under state board of pharmacy oversight [16]. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed practitioner. Pennsylvania has several licensed 503A compounding pharmacies that prepare amphetamine formulations, though availability varies by region.

The key legal distinction: 503A pharmacies may compound for individual patients, while 503B outsourcing facilities are permitted to produce larger batches but face stricter FDA oversight. During the Adderall shortage, FDA enforcement discretion allowed some 503B facilities to supply compounded amphetamine products, though that policy has evolved and patients should confirm current FDA guidance before assuming 503B-sourced product is available [4].

Cost for compounded mixed amphetamine salts from a Pennsylvania 503A pharmacy ranges from $0 (when covered under a specific insurance arrangement) to approximately $80 to $150 per month cash-pay. The $0 figure applies primarily when a patient's insurer has a contract with the specific compounding pharmacy, which is uncommon but does occur in certain employer self-insured plans. Cash-pay compounding costs reflect the pharmacy's ingredient and professional fees rather than a national wholesale price, so they vary considerably [17].

Patients should verify three things before using a compounded stimulant: (1) the compounding pharmacy holds a current Pennsylvania license, verifiable through the Pennsylvania State Board of Pharmacy; (2) the prescribing provider has documented a valid patient-specific reason for the compounded formulation rather than a commercially available equivalent; and (3) the product will be tested for potency and sterility per USP Chapter 795 standards [16].

The FDA's guidance on compounded drug products notes that compounded drugs lack the same safety and efficacy data as FDA-approved products, and that this distinction should be part of the informed consent conversation between prescriber and patient [18].

Telehealth Prescribing of Adderall XR in Pennsylvania

Pennsylvania permits telehealth prescribing of Schedule II controlled substances for established patients under both state law and the federal DEA's temporary policy extensions that have been renewed through 2025 and into 2026 [19]. An "established patient" in Pennsylvania telehealth law generally means the provider has conducted at least one clinical interaction sufficient to establish a bona fide prescriber-patient relationship.

New patients seeking a first-time stimulant prescription via telehealth occupy more ambiguous regulatory territory. The DEA's proposed Special Registration rule for telemedicine prescribing of controlled substances would require at least one in-person visit before a Schedule II drug could be prescribed via telehealth to a new patient [19]. As of mid-2026, the final rule has not been published, and prescribers are operating under the extended COVID-era flexibilities. Patients should ask any telehealth platform explicitly whether their specific clinical situation qualifies.

Pennsylvania's State Board of Medicine requires that telehealth visits for controlled substance prescribing include a documented clinical evaluation, review of the Pennsylvania Prescription Drug Monitoring Program (PDMP), and informed consent consistent with in-person standards [20]. PDMP review is mandatory before prescribing Schedule II stimulants in Pennsylvania and applies to both in-person and telehealth visits [20].

A 2023 JAMA Psychiatry study (N=5,671) found that telehealth ADHD care was associated with comparable medication adherence rates versus in-person care at 12 months, which supports the clinical validity of telehealth as an access pathway for Pennsylvania patients in rural counties where in-person psychiatrists are scarce [21].

The Adderall Shortage and Its Effect on Pennsylvania Patients

The FDA first declared a national shortage of amphetamine mixed salts in October 2022, citing manufacturing delays at Teva's primary production facility [4]. That shortage has persisted, with periodic regional availability gaps affecting Pennsylvania pharmacies through 2025 and into 2026. Pennsylvania's large population and high density of retail pharmacies means that supply varies block by block within cities like Philadelphia and Pittsburgh.

Practical steps for Pennsylvania patients who cannot find their prescribed dose in stock:

• Call at least three pharmacies before assuming a dose is unavailable statewide. Pharmacies are not required to disclose stock levels by phone under most circumstances, but many will confirm shortage status.
• Ask the prescriber whether a different amphetamine salt formulation (such as dextroamphetamine immediate-release or lisdexamfetamine) is clinically appropriate as a bridge [22].
• Request that the prescriber contact the dispensing pharmacy directly, since pharmacist-to-prescriber calls about therapeutic alternatives move faster than patient-initiated requests.
• Check the FDA's drug shortage database at fda.gov for current status before driving to a pharmacy [4].

The American Academy of Child and Adolescent Psychiatry issued a clinical resource in 2023 noting that untreated ADHD during shortage periods is associated with increased accident risk, academic decline, and worsening comorbid anxiety, underscoring that the shortage is a patient safety issue and not merely a convenience problem [23].

Comparing Total Annual Costs: A Side-by-Side Framework

Annual cost for Adderall XR in Pennsylvania depends heavily on coverage status. The table below reflects approximate 2026 figures for a 20 mg once-daily regimen.

| Coverage Scenario | Monthly Cost | Annual Cost | |---|---|---| | No insurance, no card (brand list price) | ~$260 | ~$3,120 | | No insurance, GoodRx card (generic) | ~$30 | ~$360 | | PA Medicaid (generic, Tier 2) | $1 to $3 | $12 to $36 | | Commercial insurance (generic, Tier 1) | $10 to $20 | $120 to $240 | | Commercial insurance (brand, Tier 3) | $80 to $130 | $960 to $1,560 | | Teva savings card + commercial insurance | ~$30 | ~$360 | | Compounded 503A (cash-pay) | $80 to $150 | $960 to $1,800 | | Compounded 503A (insured, contracted pharmacy) | $0 | $0 |

The data above illustrate that a Pennsylvania Medicaid enrollee paying $1 to $3 per fill spends 98% less than an uninsured patient paying the brand list price. The gap is not a quirk of one plan; it reflects the systematic discount architecture of government purchasing and Medicaid rebates authorized under 42 U.S.C. § 1396r-8 [11].

Dosing, Clinical Pharmacology, and Why Dose Affects Cost

Adderall XR doses approved by the FDA range from 5 mg to 30 mg once daily for adults, with pediatric starting doses as low as 5 to 10 mg [1]. Higher doses increase cost proportionally in some pharmacy pricing models, though generic pricing curves are less steep than brand pricing curves. A patient titrated from 10 mg to 30 mg may see a $5 to $15 increase in monthly cost with GoodRx but a $40 to $80 increase at the brand list price.

The pharmacokinetic profile of the extended-release capsule produces a bimodal plasma curve: approximately 50% of the mixed amphetamine salts release immediately and the remaining 50% release four hours later, mimicking twice-daily dosing in a single capsule [1]. This profile was designed to cover the school or work day without requiring a midday dose, which has adherence and privacy implications for pediatric patients.

A 2018 meta-analysis published in The Lancet Psychiatry (N=10,296 across 133 trials) found that amphetamines were among the most effective pharmacological treatments for ADHD in children, with a standardized mean difference of 0.79 compared to placebo, a magnitude considered large by conventional effect size benchmarks [24]. Pennsylvania providers and patients can cite this evidence when appealing insurance denials that characterize stimulant therapy as "not medically necessary."

What Pennsylvania Patients Should Bring to Their Next Appointment

Arriving prepared shortens the prescriber visit and improves the chance of leaving with the most cost-effective prescription. Bring the following:

• A printed or digital copy of your insurer's current formulary tier for amphetamine salts ER (download from member portal the day before).
• Your GoodRx or RxSaver app open and showing the price at three nearby Pennsylvania pharmacies, so the prescriber can write for the specific strength and manufacturer if applicable.
• PDMP history printed or accessible; the prescriber must check it, and having it ready reduces appointment friction [20].
• A list of prior medications tried, including doses and reason for discontinuation, to support any prior authorization appeal.
• Documentation of ADHD symptoms using a validated scale such as the Adult ADHD Self-Report Scale (ASRS) or the Conners Rating Scale for pediatric patients, which strengthen the clinical record supporting medical necessity [25].

The ASRS version 1.1 was validated in a World Health Organization-sponsored study across six countries and has a sensitivity of 68.7% and specificity of 99.5% for adult ADHD at the standard cutoff, making it a defensible clinical instrument for both diagnosis and insurance appeal documentation [25].